Facial recognition app uses AI to help ID genetic disorders

A mobile application can help healthcare professionals make genetic evaluations by using a snapshot of a person’s face, artificial intelligence and insights from real patients and genetics experts.

Face2Gene is a facial recognition app that analyzes patient photos to find specific phenotypes that could be related to a genetic disorder. It’s designed to be used only by healthcare professionals and requires a verification process.

According to the application’s website, the software uses deep learning algorithms to create syndrome-specific, computational-based classifiers (syndrome gestalts). The application and its software also uses crowd-sourced data from genetics experts, labs and patients to help match phenotypes to genetic disorders.

“Proprietary technology converts a patient photo into de-identified mathematical facial descriptors. The patient’s facial descriptor is compared to syndrome gestalts to quantify similarity (gestalt scores), resulting in a prioritized list of syndromes with similar morphology,” the Face2Gene website said. “Artificial intelligence suggests likely phenotypic traits and genes to assist in feature annotation and syndrome prioritization.”

Face2Gene also uses strong security measures to ensure patient information is protected, according to its website.

When patient photos are uploaded, the app only uses de-identified facial data while analyzing the photo. The app is also compliant with HIPAA and European Union data privacy rules and standards.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.